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ABSTRACT
Kaposi’s sarcoma is an angioproliferative
neoplasm which has undergone considerable
epidemiologic change since the original
description by Moritz Kaposi in the late 1800s.
This opportunistic neoplasm gained widespread
notoriety within the US during the height of the
AIDS epidemic, where it was frequently found
co-occurring with opportunistic infections.
With the advent of modern antiretroviral
therapies, as well as an increasing number of
individuals on immunosuppression for
autoimmune disease or organ transplantation,
the landscape of the immunocompromised
individual has changed. It is now important
for clinicians to be mindful of Kaposi’s sarcoma
manifesting in a growing variety of clinical
contexts.
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THE FOUR EPIDEMIOLOGICAL
FORMS OF KAPOSI’S SARCOMA
AIDS-Associated Kaposi’s Sarcoma
Kaposi’s sarcoma (KS) is a multi-focal,
angioproliferative neoplasm that usually
appears on the skin, but can also involve the
visceral organs. In 1981, 26 cases of KS were
reported as occurring in young homosexual
men in New York and California. Many of these
patients also had concomitant pneumocystis
carinii pneumonia (PCP) and a variety of other
‘‘opportunistic infections’’ [1]. At that time, the
underlying cause of AIDS was unknown, but,
remarkably, one-third of these patients
developed a disseminated form of KS. In 1983,
it was postulated that KS was driven by the
host’s profoundly immunocompromised state.
Interestingly, 95% of these cases had occurred
in homosexual men. Furthermore, it appeared
that the clinical presentation of AIDS-associated
KS (AIDS-KS) differed significantly from
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previously described clinical variants of this
unusual neoplasm [2]. In these
immunocompromised patients, KS behaved
more aggressively, often involving mucosal
tissues, and progressed to visceral involvement
leading to organ dysfunction and death [3].
In the early 1980s, a significant proportion of
homosexual men with AIDS were affected by
KS; for example, in San Francisco, this
opportunistic neoplasm occurred in 40% of
homosexual men with AIDS. This suggested
that a major risk factor for KS might be
homosexual intercourse [4]. In fact, several
early studies showed a connection between
the number of sexual partners and the
prevalence of KS. For example, in Vancouver,
56% of homosexual men with AIDS and more
than 20 partners developed KS [5]. As the
widespread use of highly active antiretroviral
therapy (HAART) gained popularity in the early
and mid-1990s, an 8.8% annual decline from
1990 to 1998 in KS incidence in the United
States was observed, along with a 50% reduction
in KS incidence among those on triple
antiretroviral therapy [6]. A cancer surveillance
program in San Francisco revealed similar
patterns, with the incidence of KS in 1973
(prior to the AIDS epidemic) at 0.5 cases per
100,000 people, while during the peak of the
AIDS epidemic in 1991, this number was 33.3
cases per 100,000 people and then declined in
1998 (post-HAART) to 2.8 cases per 100,000
people [7].
The Classic Form
In 1872, Moritz Kaposi first described the
‘‘classic’’ variant of KS that is typically
observed in elderly men of Mediterranean or
eastern European origin [8]. This form of KS
generally presents with lesions confined to the
lower extremity, affects men more commonly
than women in a 15:1 ratio, and is usually
indolent with patients living 10 years or more
[9]. The incidence of KS in the Mediterranean is
significantly higher than in the rest of Europe
and the United States. For example, prior to the
AIDS epidemic, there was a two- to threefold
higher prevalence of KS among the Italian
population compared to that of the USA, and
a ten times greater prevalence compared to
England [10].
The Endemic Form
In the 1950s, an endemic form of KS was
reported to be one of the most common
neoplasms observed in central Africa, affecting
men, women and children [11]. Notably,
following the AIDS epidemic, the incidence of
KS in Africa increased markedly, and from 1968
to 1970, KS accounted for 6.6% of all cancers
occurring in men; however, from 1989 to 1991,
KS became the most commonly reported cancer
occurring in men (48.6% of male cancer
patients), while the prevalence in female
cancer patients rose to 17.9% [12].
The Iatrogenic Form
In the 1970s, an ‘‘iatrogenic’’ form of KS was also
observed among organ transplant recipients, as
well as other patients on long-term
immunosuppression for other diseases [2].
Recently, there have been a growing number
of cases of this iatrogenic variant of KS. For
example, there are an increasing number of
reports in the literature describing individuals
who develop KS arising in the context of
long-term corticosteroid therapy and other
biologic therapies, including rituximab,
infliximab, and abatacept administered for
chronic inflammatory and autoimmune
conditions, including autoimmune
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thrombocytopenia, polyangiitis and pemphigus
vulgaris [13–15]. The occurrence of KS in such
patients frequently resolves spontaneously
when the immunosuppressive therapies are
discontinued [16]. As the increasing use of
these immunomodulatory medications
becomes more widespread, it is important to
be aware of the possibility of KS occurring
among these individuals who previously had
not been considered ‘‘high-risk’’.
New attention has been focused on the
increased occurrence of KS among patients
who are significantly immunosuppressed
following organ transplantation. In fact, the
incidence of KS is 400–500 times higher among
such patients than the general population [17].
This may be due to reactivation of latent HHV-8
virus or perhaps through acquisition of the
virus from the donor organ [18]. However,
certain immunosuppressants may be less likely
to put patients at risk for iatrogenic KS. For
example, sirolimus or everolimus (mTOR
inhibitors) appear to inhibit the occurrence
and/or progression of KS in transplant
recipients while preventing organ rejection
[19, 20]. These drugs may reduce the effect of
vascular endothelial growth factor (VEGF)
which is believed to play a pivotal role in the
pathogenesis of KS [20]. Therefore, clinicians
need to be aware of the oncogenic potential of
immunosuppressive therapy in these organ
transplant recipients.
PATHOGENESIS
For many years, the cause of KS was initially
perplexing, with the occurrence of KS in
patients such as those on long-term
immunosuppressant therapy strongly
suggesting the possibility that this neoplasm
might be related to a transmissible agent.
Interestingly, in the 1990s, there were also
case reports of KS occurring in gay or bisexual
HIV-negative immunocompetent individuals,
supporting the hypothesis that KS was a
neoplasm that could be due to a sexually
transmitted infection occurring within that
community [21]. It still remains unclear
exactly why KS is almost exclusively observed
in homosexual AIDS patients, and is very rarely
if ever observed in IV drug users, or in
individuals receiving blood products through
transfusions, such as hemophiliacs. Perhaps the
pathogenesis of KS may be
hormone-dependent, which would account for
the predominance in males and for the
observation that KS is transferred between
men through homosexual intercourse more
commonly than from a male to a female
partner through heterosexual intercourse [22].
In 1996, a newly discovered virus was found
to be associated with every specimen of KS
examined. Kaposi’s sarcoma-associated
herpesvirus (KSHV), now known as human
herpesvirus-8 (HHV8), was sequenced and
identified as the infectious agent previously
associated with KS among different
populations, including individuals in Eastern
Europe, Africa and the United States [23]. Since
this discovery, new research has shed light on
the molecular mechanisms of KS. The lesions
found in KS are known to contain several cell
types, such as infiltrating inflammatory cells,
endothelium and spindle cells, which have
been postulated to derive from either vascular
or lymphatic precursors. One paper has shown a
monoclonal antibody that stains specifically for
lymphatic endothelium and also stains spindle
cells from KS lesions, suggesting that the tumor
cell of KS may be of lymphatic origin [24].
Moreover, spindle cell viability is likely
dependent on the tumor milieu, which in KS
consists of elevated levels of growth factors and
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cytokines, such as interleukin (IL)-1, IL-6,
platelet-derived growth factor, tumor necrosis
factor, IFN-gamma, and VEGF [25].
In HIV-infected individuals, Th1-type
cytokines have been suggested to potentiate
KSHV activation, which can lead to an increased
viral load and a greater likelihood of the
development of KS [26]. Also, HIV-1-associated
trans-activating regulatory (Tat) protein is
needed for replication of the HIV virus and is
also released from acutely infected T cells. This
protein may induce KS by stimulating
proangiogenic chemokines, and by enhancing
KS cell growth by synergizing with basic
fibroblast growth factor (bFGF), which is an
essential factor for lesion formation [3]. This
may account for the more aggressive behavior
of KS lesions in HIV-infected individuals
compared to the classic variant [27]. However,
the Tat protein is only able to interact with
endothelial cells through a RGD motif, which is
absent in HIV-2. This may explain why KS is less
commonly found in individuals with HIV-2
compared to HIV-1 infection [28].
TREATMENT
A variety of treatment options are available for
the classic variant of KS. Since these lesions
often recur, but are less often life-threatening,
one viable treatment strategy is recurrent use of
local cryotherapy which typically resolves the
isolated lesions [29]. Another well-described
approach is the use of intralesional
chemotherapeutics such as vincristine which
are also efficacious [30].
For patients with extensive disease and/or
widespread rapidly progressive disease, it may
be necessary to resort to more generalized
therapies. Pegylated liposomal doxorubicin has
been used as a first-line treatment, with a
favorable 71% response rate, and is
significantly better tolerated than traditional
chemotherapeutics [31, 32]. Another option is
the use of localized radiation to the lower
extremity which has shown a high rate of
resolution to the affected fields [33].
Kaposi’s sarcoma occurring in patients on
significant immunosuppression will resolve in
the majority of patients when the
immunosuppressive therapy is altered, reduced
or discontinued. Commonly, when KS arises in
renal transplant recipients, a decrease in the
level of immunosuppression is a first reasonable
strategy [34]. When this does not promote
resolution of the disease, or begins to
compromise graft viability, some patients may
benefit from transition of typical calcineurin
inhibitors such as cyclosporine to proliferation
signal inhibitors such as sirolimus, which often
results in complete resolution of active KS
without rejection of the graft [20].
The mainstay of treatment for AIDS-related
KS involves the initiation of HAART, which
typically results in a subsequent decrease in
tumor burden as the CD4 count rises and is able
to adequately suppress the HHV8 virus.
Interestingly, a subset of these patients may
experience a progression of their disease
following initiation of HAART in an immune
reconstitution inflammatory syndrome (IRIS)
[35, 36]. Typically, these patients are able to
continue therapy, but in some cases adjuvant
chemotherapy may be required to control the
tumor burden.
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